nitroflurbiprofen has been researched along with thromboxane a2 in 1 studies
| Studies (nitroflurbiprofen) | Trials (nitroflurbiprofen) | Recent Studies (post-2010) (nitroflurbiprofen) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 58 | 1 | 6 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fevery, J; Laleman, W; Nevens, F; Van der Elst, I; Van Landeghem, L; Zeegers, M | 1 |
1 other study(ies) available for nitroflurbiprofen and thromboxane a2
| Article | Year |
|---|---|
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Flurbiprofen; Hypertension, Portal; Kidney Diseases; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Male; Nitric Oxide; Nitric Oxide Donors; Peptic Ulcer; Perfusion; Portal Pressure; Rats; Rats, Wistar; Thioacetamide; Thromboxane A2; Vascular Resistance; Vasoconstriction; Vasodilation | 2007 |